Stockscreener 앱 받기
60.74
1.47%
0.88
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Bristol Myers (BMY) Receives FDA Orphan Drug Status for Follicul - GuruFocus
Here's What Analysts Are Saying About Bristol-Myers Squibb Company (BMY) - Finviz
Here’s What Analysts Are Saying About Bristol-Myers Squibb Company (BMY) - Insider Monkey
Bristol Myers Squibb signs to Life Science Cares National Campaign to advance health equity and fight food insecurity - ROI-NJ
Bristol-Myers Squibb Co (BMY) Stock Price, Trades & News - GuruFocus
LSV Asset Management Purchases 138,119 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Rhumbline Advisers - MarketBeat
Krilogy Financial LLC Grows Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company (NYSE:BMY) Given Average Rating of "Hold" by Brokerages - MarketBeat
Illinois Municipal Retirement Fund Increases Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Caisse Des Depots ET Consignations Sells 21,113 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Company (BMY) Growth Portfolio Driving Earnings Growth - Insider Monkey
The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb's Q4 Earnings Call - Finviz
What Does the Market Think About Bristol-Myers Squibb Co? - Sahm
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY) - GuruFocus
BRISTOL MYERS SQUIBB CO SEC 10-K Report - TradingView
Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
SC refuses stay on Zydus cancer drug launch, tells BMS to seek relief in HC - Business Standard
Wealthfront Advisers LLC Sells 17,324 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Oral Anticoagulants Market Is Going to Boom |• Bristol-Myers Squibb • Johnson & Johnson - openPR.com
ING Groep NV Boosts Position in Bristol Myers Squibb Company $BMY - MarketBeat
Hepatitis B Treatment Market Size is Projected to Reach USD 7.74 Billion by 2033 Due to the Increasing Disease Management Trends Globally - GlobeNewswire Inc.
Zydus Life cleared to sell life-saving cancer drug; SC tells Bristol Myers to map patents - The Economic Times
Bristol Myers Squibb’s Stock Is On Sale: Value Trap Or Deep-Value Turnaround Play? - AD HOC NEWS
Is Bristol Myers Squibb (BMY) Pricing Reflecting Its Recent Share Price Rebound? - Yahoo Finance
Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating - TipRanks
Bristol-Myers Squibb stock rating reiterated by Bernstein at Market Perform - Investing.com India
Bristol-Myers Squibb (BMY) Is Up 8.7% After Profit Rebound And Pipeline OutlookHas The Bull Case Changed? - Yahoo Finance
Bristol Myers Squibb AI Trials And 2026 Readouts Reframe Valuation - Yahoo Finance
Bristol-Myers Squibb (BMY) Is Up 8.7% After Swing To Profit And AI-Focused R&D Push - simplywall.st
Assessing Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Pipeline Optimism - Yahoo Finance UK
Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating - Finviz
Bristol Myers Squibb Company $BMY Shares Sold by Envestnet Asset Management Inc. - MarketBeat
Candriam S.C.A. Cuts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence - Yahoo Finance
Kinsale Capital Group Inc. Has $7.61 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Stock Is On Sale: Smart Buy Or Value Trap You’ll Regret? - AD HOC NEWS
Bristol-Myers Squibb Stock: Dividend Giant Under Pressure or Deep-Value Setup? - AD HOC NEWS
Jim Cramer Discusses Bristol Myers's (BMY) Cobenfy Drug - Finviz
Jim Cramer Discusses Bristol Myers’s (BMY) Cobenfy Drug - Insider Monkey
Birmingham Capital Management Co. Inc. AL Reduces Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Returns To US$7.1b Trailing Profit Challenging Bearish Narratives - simplywall.st
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim - Investing.com UK
Bristol-Myers Squibb stock price target raised to $60 by Wells Fargo - Investing.com UK
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026 (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb (NYSE:BMY) Given New $64.00 Price Target at Citigroup - MarketBeat
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim By Investing.com - Investing.com India
Bristol-Myers Squibb Co (NYSE:BMY) Tops Estimates - FXDailyReport.Com
Bristol-Myers Squibb Co (BMY) Stock Price Up 3.76% on Feb 6 - GuruFocus
Wells Fargo Raises Price Target for Bristol-Myers Squibb (BMY) | BMY Stock News - GuruFocus
What Catalysts Are Rewriting The Story For Bristol Myers Squibb (BMY)? - Yahoo Finance
Bristol Myers Squibb Company $BMY Shares Sold by Wells Trecaso Financial Group LLC - MarketBeat
Bristol-Myers Squibb Company (NYSE:BMY) Q4 2025 Earnings Call Transcript - Insider Monkey
Bristol-Myers Squibb Co. (BMY) PT Raised to $72 at Guggenheim - StreetInsider
BMS reports flat revenue growth for full-year 2025 - Pharmaceutical Technology
BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus - Finviz
Bristol Myers Squibb stock gets positive readthrough from Bayer stroke data - Investing.com
Bristol Myers Squibb Q4 Earnings Call Highlights - Yahoo Finance
Bristol-Myers Squibb (BMY) Exceeds Q4 Earnings Expectations - GuruFocus
0.40%
자본화:
|
볼륨(24시간):